Drug intelligence / Profile preview

ACD680

Development stage: Preclinical
Lead developer: AlzeCure Pharma
Modality: Small Molecules
Administration: Oral

Overview

ACD680, also known as Alzstatin, is a drug candidate being developed by AlzeCure Pharma, a Swedish biotech company focused on central nervous system (CNS) diseases. It is specifically being advanced for the treatment of Alzheimer's disease and is slated for first-in-human trials.

Other names: Alzstatin

Targets

GSEC (Gamma-Secretase Complex)

Beyond the preview

Go deeper on ACD680.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACD680.

Explore the full profile